Title {1}	A Phase 3 Randomized, Double-blind, Placebo-controlled, Multicentre Study to Evaluate the Efficacy and Safety of Intravenous Remdesivir in Adult Patients With Severe Pneumonia caused by COVID-19 virus Infection
Trial registration {2a and 2b}	ClinicalTrials.gov NCT04257656
Protocol version {3}	Version 3.0 09 February 2020
Funding {4}	Funded by: • Emergency project for novel coronavirus pneumonia of the Ministry of Science and Technology (2020YFC0841300) • Chinese Academy of Medical Sciences (CAMS) Innovation Fund for Medical Sciences (CIFMS 2018-I2M-1-003) • National Science Grant for Distinguished Young Scholars (81425001/H0104) • The National Key Research and Development Program of China (2018YFC1200102) • The Beijing Science and Technology Project (Z19110700660000) • National Mega-projects for Infectious Diseases in China (2017ZX10103004 and 2018ZX10305409). Other support: • China Evergrande Group, Jack Ma Foundation, Sino Biopharmaceutical Limited, Ping An Insurance (Group), New Sunshine Charity Foundation, International Severe Acute Respiratory and emerging Infections Consortium (ISARIC) • NIHR Senior Research Fellowship (TJ: 2015-08-001)
Author details {5a}	Department of Pulmonary and Critical Care Medicine, Center of Respiratory Medicine, National Clinical Research Center for Respiratory Diseases, China-Japan Friendship Hospital, Beijing, China Jin Yin-tan Hospital, Wuhan, Hubei Province, China; Tongji Hospital, Tongji Medical College of Huazhong University of Science & Technology, Wuhan, Hubei Province, China; Wuhan Lung Hospital, Wuhan, Hubei Province, China; The Central Hospital of Wuhan, Wuhan, Hubei Province, China; Zhongnan Hospital of Wuhan University, Wuhan, Hubei Province, China; Renmin Hospital of Wuhan University, Wuhan, Hubei Province, China; Union Hospital, Tongji Medical College of Huazhong University of Science & Technology, Wuhan, Hubei Province, China; Wuhan First Hospital, Wuhan, Hubei Province, China; Wuhan Third Hospital, Wuhan, Hubei Province, China; Wuhan Fourth Hospital, Wuhan, Hubei Province, China; Institute of Respiratory Medicine, Chinese Academy of Medical Sciences, Beijing, China; Institute of Clinical Medical Sciences, China-Japan Friendship Hospital, Beijing, China; Lancaster University, Lancaster, UK; University of Virginia School of Medicine, Charlottesville, VA, USA; University of Oxford, Oxford, UK; Peking Union Medical College, Beijing, China
Name and contact information for the trial sponsor {5b}	China-Japan Friendship Hospital, Beijing, People’s Republic of China
Role of sponsor {5c}	The study sponsor and funders had no role in study design; collection, management, analysis, or interpretation of data; writing of the report; or the decision to submit the report for publication